PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine.

Abstract Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the United States, has announced that their stock of YF-VAX is totally depleted as of July 24, 2017. YF-VAX for civilian use will be unavailable for ordering from Sanofi Pasteur until mid-2018, when their new manufacturing facility is expected to be completed. However, YF-VAX might be available at some clinics for several months, until remaining supplies at those sites are exhausted. In anticipation of this temporary total depletion, in 2016, Sanofi Pasteur submitted an expanded access investigational new drug application to the Food and Drug Administration to allow for importation and use of Stamaril. The Food and Drug Administration accepted Sanofi Pasteur's application in October 2016.
PMID
Related Publications

Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.

Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017.

Authors

Mayor MeshTerms

Drugs, Investigational

Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28749924
OWN - NLM
STAT- MEDLINE
DA  - 20170727
DCOM- 20170731
LR  - 20170731
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 29
DP  - 2017 Jul 28
TI  - Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for
      Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril
      Vaccine.
PG  - 780
LID - 10.15585/mmwr.mm6629a4 [doi]
AB  - Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX)
      licensed in the United States, has announced that their stock of YF-VAX is
      totally depleted as of July 24, 2017. YF-VAX for civilian use will be unavailable
      for ordering from Sanofi Pasteur until mid-2018, when their new manufacturing
      facility is expected to be completed. However, YF-VAX might be available at some 
      clinics for several months, until remaining supplies at those sites are
      exhausted. In anticipation of this temporary total depletion, in 2016, Sanofi
      Pasteur submitted an expanded access investigational new drug application to the 
      Food and Drug Administration to allow for importation and use of Stamaril. The
      Food and Drug Administration accepted Sanofi Pasteur's application in October
      2016.
FAU - Gershman, Mark D
AU  - Gershman MD
AD  - Division of Global Migration and Quarantine, National Center for Emerging and
      Zoonotic Infectious Diseases, CDC.
FAU - Sotir, Mark J
AU  - Sotir MJ
AD  - Division of Global Migration and Quarantine, National Center for Emerging and
      Zoonotic Infectious Diseases, CDC.
LA  - eng
PT  - Journal Article
DEP - 20170728
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Drugs, Investigational)
RN  - 0 (Yellow Fever Vaccine)
SB  - IM
MH  - *Drugs, Investigational
MH  - Humans
MH  - Licensure
MH  - Travel
MH  - United States
MH  - Yellow Fever/*prevention & control
MH  - Yellow Fever Vaccine/*supply & distribution
EDAT- 2017/07/28 06:00
MHDA- 2017/08/02 06:00
CRDT- 2017/07/28 06:00
AID - 10.15585/mmwr.mm6629a4 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):780. doi: 10.15585/mmwr.mm6629a4.